Remicade hauls MTP to full-year growth
This article was originally published in Scrip
Executive Summary
Continued strong growth for Remicade (infliximab) meant group sales at Mitsubishi Tanabe Pharma (MTP) stayed in positive territory for the year to March 31st, but only just. Last year's general price revision in Japan and lower non-pharmaceutical sales both weighed heavily on the top line.